Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe
- Acquisition substantially expands Selvita’s integrated drug discovery services offering
- Transaction will almost double Selvita’s revenues
- Enterprise value of € 31.2M to be paid in cash
- Fidelta to continue performing drug discovery services for Galapagos for the next five years
The news that we’ve all been waiting for is out today, from the UK-sourced Oxford University and AstraZeneca COVID-19 vaccine. The great news is that the vaccine works in Phase III clinical trials. For an industry audience it is worth digging into the complex dataset.
The BioIndustry Association's Rare Disease Industry Group (RDIG) has today launched A Rare Chance for Reform in collaboration with PwC, calling for action to ensure that patients are able to access innovative medicines for rare diseases.
Breaking news today that Moderna has released initial data on their mRNA vaccine’s Phase 3 study, which met statistical criteria with a vaccine efficacy of 94.5%. The phase 3 trial was conducted in the US in partnership with BARDA and Operation Warp Speed and based on these interim safety and efficacy data, Moderna intends to submit an application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in the coming weeks. It’s great news and following last week’s announcement by Pfizer/Biontech, shows the importance of smaller biotech companies in our innovation ecosystem.
Draft legislation to implement the SME R&D tax credit PAYE cap published yesterday (12 November) confirms that the Government intends to implement a targeted exemption to protect genuine companies, as proposed by the BIA.
A report published today by the British Business Bank is the most comprehensive analysis of UK life science venture capital performance to date, and it reveals that life science investments have performed equally or better than those in non-life sciences.